Developing and testing a novel self-guided digital therapeutic solution for preventing stammering in children: incorporating latest research on early detection and progress evaluation using real-world data

** 需要 ** 口吃通常在2至6岁之间开始，25%的受影响儿童在青春期成为慢性。它影响了全球8%的儿童和2%的青少年和成年人。早期发现幼儿口吃对于有效的干预和治疗至关重要。然而，目前可用的检测口吃的工具是为言语和语言治疗师（SLT）设计的，而长期等待使用SLT可能会加剧心理健康挑战。项目机会 **Respira是一家英国中小企业，旨在通过该项目开发一种新的治疗解决方案，用于口吃儿童的早期检测和进展评估，父母、监护人和护理人员（PGC）可以在没有家长支持的情况下使用和解释口吃。在之前的Innovate UK赠款的支持下，Respira建立了BeneTalk：数字治疗解决方案，为慢性口吃提供可访问的，有效的和持续的支持。该项目旨在通过利用现有的BeneTalk专业知识/框架/能力开发一种新的解决方案，从而扩大Respira的市场份额。该项目开发的诊断和评估工具也将允许Respira通过使用真实世界的数据生成证据来评估该项目的有效性。该项目将对Respira的技术和商业影响产生变革性影响，增加其TAM，在税收和就业方面对英国经济的影响 **最新技术水平 ** 目前还没有数字治疗解决方案可用于口吃儿童（CWS）的PGC。目前的护理标准是使用SLT进行面对面治疗，这些治疗有限或昂贵，并且没有诊所外或治疗后的支持。该项目将与Lidcombe计划和佩林亲子互动疗法兼容，这是标准的治疗实践。这将提高该项目的采用率，并实现更好的治疗效果。**更广泛的影响 ** 该项目将通过使语言治疗民主化来改变CWS和PGC的生活：它将通过解决焦虑，抑郁和其他影响两者的心理健康状况来改善心理健康。开发和商业化该项目将提供一个具有成本效益的解决方案，以解决由于“邮政编码”彩票影响英国语言治疗途径而造成的不平等问题。该项目将使言语治疗能够在家中进行，并减少面对面预约和随访的需要，估计比护理标准绿色1500倍。发展这样一个人道主义企业有利于英国经济，因为它创造了高技能的就业机会，征收了税收，并建立了国家品牌。

**Need**Stammering typically begins between the ages of 2 and 6, and becomes chronic in adolescence for 25% of affected children. It affects 8% of children globally and 2% of teenagers and adults. Early detection of stammering in young children is crucial for effective intervention and treatment. However, currently available tools for detecting stammering are designed for speech and language therapists (SLTs), and long waiting lists to access SLTs can worsen mental health challenges.**Project Opportunity**Respira, a UK SME, aims to develop in this project a new therapeutic solution for early detection and progress evaluation of stammering in children who stammer that parents, guardians and caregivers (PGCs) can use and interpret without SLT support.With the support of a previous Innovate UK grant, Respira built BeneTalk: a digital therapeutic solution to provide accessible, effective, and ongoing support for chronic stammering. This project aims to develop a new solution, by leveraging existing BeneTalk expertise/framework/capabilities, thus expanding Respira's market share.The diagnostic and evaluation tools developed in the project will allow also Respira to assess the effectiveness of this project by using real-world data for evidence generation.The project will have a transformative effect on Respira's technical and commercial impact, increasing its TAM, and on the UK economy in terms of taxes and employment.**State-of-the-Art**There are no digital therapeutic solutions available for PGCs of children who stammer (CWS). The current standard of care is face-to-face therapy sessions with SLTs, which are limited or expensive, and without support outside the clinic or post-therapy. This project will be compatible with both the Lidcombe Programme and Palin Parent-Child Interaction Therapy, which are standard treatment practices. This will increase the adoption of this project and achieve better therapy outcomes.**Wider Impact**The project will transform the lives of CWS and PGCs by democratising access to speech therapy: It will improve mental health by addressing anxiety, depression, and other mental health conditions that affect both.Developing and commercialising this project will provide a cost-effective solution to tackle inequality due to the "postcode" lottery affecting UK speech therapy pathways. This project will enable the delivery of speech therapy in the home and reduce the need to travel to face-to-face appointments and follow-ups, which is estimated to be 1500 times greener than the standard of care. Developing such a humanitarian business benefits the UK economy due to high-skill jobs created, taxes collected, and national branding.